Neumora Therapeutics (NMRA) Non-Current Assets (2022 - 2026)

Neumora Therapeutics' Non-Current Assets history runs 5 years deep, the most recent figure standing at $443000.0 for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 76.46% year-over-year to $443000.0 in Q1 2026; TTM through Mar 2026 was $2.6 million, a 82.39% decrease from a year earlier, with the FY2025 full-year figure at $510000.0, down 82.52% from the prior year.
• Non-Current Assets eased to $443000.0 in Q1 2026 per NMRA's latest filing, from $510000.0 in the prior quarter.
• Across five years, Non-Current Assets topped out at $38.3 million in Q4 2022 and bottomed at $443000.0 in Q1 2026.
• The 5-year median for Non-Current Assets is $3.4 million (2024), against an average of $8.3 million.
• Across the five-year window, Non-Current Assets plunged 53.2% in 2023 and tumbled 85.12% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $38.3 million in 2022, then plunged by 53.2% to $17.9 million in 2023, then slumped by 83.72% to $2.9 million in 2024, then tumbled by 82.52% to $510000.0 in 2025, then dropped by 13.14% to $443000.0 in 2026.
• Per Business Quant, the three latest NMRA Non-Current Assets figures stand at $443000.0 (Q1 2026), $510000.0 (Q4 2025), and $751000.0 (Q3 2025).